The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
The company had responded to the agency and carried out the required corrective actions.
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
The product is expected to be launched by Q4 FY23.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is focussed on increasing the capacity utilizations while controlling costs
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
Subscribe To Our Newsletter & Stay Updated
